论文部分内容阅读
目的探讨去甲基化药物联合减量预激方案治疗中高危骨髓增生异常综合征(MDS)的效果和不良反应。方法采用回顾性分析,随机选取收治的40例MDS初治患者,20例采用去甲基化药物联合减量预激方案治疗,20例采用标准化疗治疗。均于第一疗程结束后进行初步的疗效评价,治疗显效者进入第二疗程治疗,无效者不再观察。两个疗程结束后对比观察两组患者的治疗效果和不良反应。结果去甲基化药物联合减量预激方案组完全缓解率为45%,总体有效率为70%。标准化疗方案组完全缓解率25%,总体有效率为40%。去甲基化药物联合减量预激方案组与标准化疗组的完全缓解率和总有效率均存在显著差异(P<0.05),部分缓解率不存在显著差异(P<0.05)。去甲基化药物联合减量预激方案组的不良反应好于标准化疗组。结论去甲基化药物联合减量预激方案治疗中高危骨髓增生异常综合征疗效显著,安全性较高。
Objective To investigate the efficacy and adverse reactions of demethylation combined with reduced-dose pre-stimulation regimen in the treatment of middle-high risk myelodysplastic syndrome (MDS). Methods A retrospective analysis was used to select 40 patients with MDS who were initially treated. 20 patients were treated with demethylation combined with antidepressant and 20 patients were treated with standard chemotherapy. Are in the first course of treatment after the initial evaluation of efficacy, effective treatment of those who entered the second course of treatment, ineffective no longer observed. After two courses of treatment were compared between the two groups observed treatment and adverse reactions. Results The complete remission rate was 45% and the overall effective rate was 70%. The standard chemotherapy regimen complete remission rate of 25%, the overall effective rate was 40%. There was a significant difference (P <0.05) in the complete remission rate and the total effective rate between the demethylation combined descendent stimulation group and the standard chemotherapy group, with no significant difference in the partial remission rate (P <0.05). Adverse reactions to demethylation combined with anti-stress program were better than the standard chemotherapy group. Conclusions The combination of demethylation and weight loss pre-stimulation is effective and safe in treating middle-high risk myelodysplastic syndromes.